J. L. Steegmann

2.2k total citations
14 papers, 374 citations indexed

About

J. L. Steegmann is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, J. L. Steegmann has authored 14 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 10 papers in Genetics and 5 papers in Rheumatology. Recurrent topics in J. L. Steegmann's work include Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Eosinophilic Disorders and Syndromes (5 papers). J. L. Steegmann is often cited by papers focused on Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Eosinophilic Disorders and Syndromes (5 papers). J. L. Steegmann collaborates with scholars based in Spain, Germany and Italy. J. L. Steegmann's co-authors include Michele Baccarani, Martin Dreyling, S. Pileri, Marc Müller, Simona Soverini, Rafael de la Cámara, J Odriozola, Lucı́a Villalón, Francisco Cervantes and Joaquín Martínez‐López and has published in prestigious journals such as Blood, Annals of Oncology and Leukemia.

In The Last Decade

J. L. Steegmann

14 papers receiving 363 citations

Peers

J. L. Steegmann
Matthias Klammer United Kingdom
S Miyawaki Japan
Ryan McGee United States
Montserrat Rafel Spain
Elisabetta Calistri Italy
Gioia Colafigli Italy
Adriano Salaroli Italy
Janna Rudolph Germany
L.B. To Australia
Matthias Klammer United Kingdom
J. L. Steegmann
Citations per year, relative to J. L. Steegmann J. L. Steegmann (= 1×) peers Matthias Klammer

Countries citing papers authored by J. L. Steegmann

Since Specialization
Citations

This map shows the geographic impact of J. L. Steegmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. L. Steegmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. L. Steegmann more than expected).

Fields of papers citing papers by J. L. Steegmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. L. Steegmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. L. Steegmann. The network helps show where J. L. Steegmann may publish in the future.

Co-authorship network of co-authors of J. L. Steegmann

This figure shows the co-authorship network connecting the top 25 collaborators of J. L. Steegmann. A scholar is included among the top collaborators of J. L. Steegmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. L. Steegmann. J. L. Steegmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Cervantes, Francisco, Juan Gonzalo Correa, Valentín García‐Gutiérrez, et al.. (2016). Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. Annals of Hematology. 96(1). 81–85. 28 indexed citations
2.
3.
Ottmann, Oliver G., A Charbonnier, Frank Stegelmann, et al.. (2015). Smoothened (Smo) Inhibitor Lde225 Combined With Nilotinib In Patients With Chronic Myeloid Leukemia (Cml) Resistant/Intolerant (R/I) To At Least 1 Prior Tyrosine Kinase Inhibitor: A Phase 1B Study. ORCA Online Research @Cardiff (Cardiff University). 4 indexed citations
4.
Baccarani, Michele, S. Pileri, J. L. Steegmann, et al.. (2012). Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 23. vii72–vii77. 69 indexed citations
5.
Guilhot, Joëlle, Michele Baccarani, Richard E. Clark, et al.. (2012). Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood. 119(25). 5963–5971. 54 indexed citations
6.
Steegmann, J. L., Mauricette Michallet, Enrica Morra, et al.. (2010). A european observational study of dasatinib in the management of imatinib-resistant and -intolerant patients with chronic myeloid leukemia: forte study (ca180-211). 95. 339–339. 1 indexed citations
7.
Villuendas, Raquel, J. L. Steegmann, Marina Pollán, et al.. (2006). Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia. 20(6). 1047–1054. 84 indexed citations
8.
Hasford, Joerg, Markus Pfirrmann, R. Hehlmann, et al.. (2003). Prognosis and prognostic factors for patients with chronic myeloid leukemia: Nontransplant therapy. Seminars in Hematology. 40(1). 4–12. 5 indexed citations
9.
Cervantes, Francisco, Juan Carlos Hernández‐Boluda, J. L. Steegmann, et al.. (2003). Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.. PubMed. 88(10). 1117–22. 35 indexed citations
10.
Forés, Rafael, et al.. (1998). De novo smoldering paroxysmal nocturnal hemoglobinuria: a flow cytometric diagnosis.. PubMed. 82(6). 695–7. 5 indexed citations
11.
Cámara, Rafael de la, et al.. (1996). Penicillium brevicompactum as the cause of a necrotic lung ball in an allogeneic bone marrow transplant recipient.. PubMed. 18(6). 1189–93. 30 indexed citations
12.
Steegmann, J. L., et al.. (1994). Erythropoietin in the treatment of delayed immune hemolysis of a major ABO‐incompatible bone marrow transplant. American Journal of Hematology. 45(3). 237–239. 5 indexed citations
13.
Cámara, Rafael de la, Á Figuera, J. L. Steegmann, et al.. (1992). Allogeneic bone marrow transplantation for high risk acute lymphoblastic leukemia. Results from a single institution.. PubMed. 9(6). 433–8. 10 indexed citations
14.
Steegmann, J. L., et al.. (1992). Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial.. PubMed. 10(6). 541–6. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthias Klammer Breakdown of academic impact, for papers by S Miyawaki Breakdown of academic impact, for papers by Ryan McGee Breakdown of academic impact, for papers by Montserrat Rafel Breakdown of academic impact, for papers by Elisabetta Calistri Breakdown of academic impact, for papers by Gioia Colafigli Breakdown of academic impact, for papers by Adriano Salaroli Breakdown of academic impact, for papers by Janna Rudolph Breakdown of academic impact, for papers by L.B. To
Rankless by CCL
2026